PHVS

NASDAQ · Pharmaceuticals

Pharvaris Nv

Mid-Cap Stocks Pharmaceutical Stocks Healthcare Stocks

$34.49

+1.96 (+6.03%)

As of Nov 7, 1:46 AM ET ·

PHVS News1 articles

Pharvaris Surges 17% as Phase 3 HAE Trial Meets Primary Endpoint

Pharvaris (PHVS) soared 17% after its oral HAE preventive met the primary endpoint in Phase 3, reducing monthly attacks by 83% versus placebo.